Immunotoxicity Endpoints
Immunotoxicity Endpoints is a scientific measurement or observation used to evaluate adverse effects of xenobiotics on the immune system, distinguished by its specific focus on immunological parameters that reflect functional, cellular, or molecular alterations indicative of immunosuppression, hypersensitivity, autoimmunity, or inflammation within the context of toxicological risk assessment.
81
Publications
2.8K
Citations
400
Authors
171
Institutions
Publications per year
2017–2026
19
81
1–5 of 81
400
National Institute of Environmental Health Sciences, United States
5 publications · 129 citations
5
h-index
Virginia Commonwealth University Medical Center, United States
4 publications · 138 citations
4
h-index
National Institute for Public Health and the Environment, Netherlands
4 publications · 204 citations
4
h-index
National Institute of Environmental Health Sciences, United States
3 publications · 149 citations
3
h-index
3
h-index
1–5 of 400
171
National Institute of Environmental Health Sciences
Durham, United States
11 h-index
27 publications
1.1K citations

Research Triangle Park Foundation
Durham, United States
7 h-index
11 publications
438 citations
National Institute for Public Health and the Environment
De Bilt, The Netherlands
6 h-index
14 publications
616 citations
Environmental Protection Agency
Washington, United States
4 h-index
6 publications
324 citations
National Institute for Occupational Safety and Health
Washington D.C., United States
3 h-index
3 publications
163 citations
National Institutes of Health
Bethesda, United States
3 h-index
10 publications
602 citations
Novartis (Switzerland)
Basel, Switzerland
3 h-index
9 publications
189 citations
GlaxoSmithKline (United States)
Philadelphia, United States
3 h-index
14 publications
624 citations
1–8 of 171
9 publications · 252 citations
9
h-index
6 publications · 251 citations
6
h-index
4 publications · 121 citations
4
h-index
4 publications · 263 citations
4
h-index
4 publications · 111 citations
4
h-index
1–5